Prostate Cancer

Adding 177Lu-PSMA-617 to ADT and an ARPI maintained health-related quality of life in patients with metastatic hormone-sensitive prostate cancer.

Final phase 3 EORTC 1333/PEACE-3 data show enzalutamide plus radium-223 extends OS and radiographic progression-free survival in mCRPC with bone metastases.

Patients with PTEN-deficient metastatic hormone-sensitive prostate cancer had improved rPFS with capivasertib plus abiraterone.

The FDA has greenlit treatment with rucaparib for previously treated patients with BRCA-mutated metastatic castration-resistant prostate cancer.

The FDA has approved niraparib and abiraterone acetate with prednisone for the treatment of patients with BRCA2-mutated metastatic hormone-sensitive prostate cancer.

Patient-reported outcomes showed that health-related QOL stayed at baseline for patients with HRRM-positive mHSPC receiving a niraparib regimen.

The combination of apalutamide to carotuximab showed early signs of tolerability in patients with metastatic castration-resistant prostate cancer.

Gedatolisib-based combinations yielded encouraging responses in patients with mCRPC and HER2-positive metastatic breast cancer, early trial data show.

Oncologic therapies approved in June included indications in genitourinary, lung, hematologic, and head and neck cancers.

Patients with metastatic CRPC who maintained PSMA expression had a median OS of 14.5 months with 177Lu-PSMA-617 retreatment.

Illuccix, a preparation kit for injectable Ga-68, has been approved to select patients for radioligand therapy before taxane chemotherapy.

The FDA approved darolutamide monotherapy for use in metastatic hormone-sensitive prostate cancer following ARANOTE findings.

The combination of niraparib with abiraterone acetate and prednisone (AAP) boosted rPFS vs AAP plus placebo in HRR-mutated mCSPC.

The FDA's ODAC voted unanimously against the risk-benefit profile of talazoparib and enzalutamide for the treatment of mCRPC lacking HRR mutations.

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in patients with prostate cancer.

Apalutamide decreased risk of death in mCSPC by 23% and 26% compared with enzalutamide and abiraterone acetate, respectively.

“When discussing treatment options with patients, it is important to consider efficacy, safety, and the impact of treatment on patients’ quality of life [QOL]…,” noted Brenda Martone, RN, APP.

Indications for 177Lu-PSMA-617 now include taxane-based chemotherapy naive adults with PSMA+ mCRPC.

Oncology nurses play a key role in advocating for metastasis-directed therapy in prostate cancer.

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected metastasis or suspected recurrence.

Two denosumab biosimilars have been approved by the FDA for all previously approved uses for the reference drugs in cancers and osteoporosis.

Men with intermediate-risk prostate cancer and high PSA levels before HIFU treatment had a greater risk of both overall recurrence and treatment failure.

Patients with metastatic hormone-sensitive prostate cancer experienced increase rPFS and other efficacy end points with darolutamide plus ADT.

MyCareGorithm was met with high approval from patients, companions, and physicians, with all 3 groups reporting they’d recommend the tool to other patients.

While lower relative dose intensity of docetaxel was associated with higher rates of G-CSF use and more adverse events, discontinuation rates were low across all groups.